The Effectiveness of Oral Vancomycin on Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis: A Systematic Review
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izae257 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Naik Arbabzada und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Vancomycin, Inflammatory Bowel Diseases, Anti-Bacterial Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Approximately 70% of primary sclerosing cholangitis (PSC) patients have inflammatory bowel disease (IBD). The IBD therapies currently used to treat PSC-IBD patients have side effects and can be costly. Oral vancomycin (OV)—a safe, economical, and convenient therapy—has been reported to be a salvage therapy in refractory PSC-IBD patients. This systematic review aims to summarize the current literature regarding the effectiveness and safety of OV to treat IBD in PSC patients.
Methods
A systematic literature review of Scopus, Embase, Web of Science, MEDLINE, and CINAHL was performed until March 2024. The Murad scale, Newcastle-Ottawa scale, and Cochrane Collaboration Risk of Bias Tool were used to determine the quality of the case reports and case series, cohort studies, and randomized controlled trial (RCT), respectively. The outcomes sought were response or remission across clinical, biochemical, endoscopic, and histological parameters.
Results
Of the 1725 published studies, we identified 9 case reports, 7 case series, 3 cohort studies, and 1 RCT. Most studies reported an improvement in clinical IBD symptoms such as diarrhea and hematochezia. Fewer publications provided supporting objective data in the form of fecal calprotectin, endoscopic Mayo scores, and histology. There were no reports of vancomycin-resistant enterococci infections.
Conclusions
Oral vancomycin appears safe and effective to treat IBD in a subset of PSC patients. Future studies would benefit from prospective data collection incorporating standardized symptomatic, endoscopic, and histologic indices. Ultimately, a well-powered RCT is needed to better assess the effectiveness, safety, and durability of OV therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
- Geoffrey and Robyn Sperber Health Sciences Library, University of Alberta, Edmonton, AB, Canada.
ORCID-Profile: Naik Arbabzada, Guanmin Meng, Farhad Peerani
Zitieren
APA
Arbabzada, N., Dennett, L., Meng, G., & Peerani, F. (2025). The Effectiveness of Oral Vancomycin on Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis: A Systematic Review. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae257
Vancouver
Arbabzada N, Dennett L, Meng G, Peerani F. The Effectiveness of Oral Vancomycin on Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis: A Systematic Review. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae257
BibTeX
@article{Arbabzada2025,
author = {Arbabzada, Naik and Dennett, Liz and Meng, Guanmin and Peerani, Farhad},
title = {The Effectiveness of Oral Vancomycin on Inflammatory Bowel Disease in Patients With Primary Sclerosing Cholangitis: A Systematic Review},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izae257}
}
EUVIMED